-
公开(公告)号：US20240117314A1
公开(公告)日：2024-04-11
申请号：US18376440
申请日：2023-10-03
Inventor： Ruei-Yue Liang , Chia-Hsin Lee , Kai-Ling Zhang , Po-Cheng Lin , Ming-Hsi Chuang , Yu-Chen Tsai , Peggy Leh Jiunn Wong
IPC: C12N5/0775 , A01N1/02 , A61K35/28 , A61P3/10
CPC classification number: C12N5/0662 , A01N1/0284 , A61K35/28 , A61P3/10 , C12N2500/32 , C12N2500/38
Abstract: The present invention relates to a method for preparing a modified stem cell, including the following steps: a cell culture step: culturing stem cells in a first culture medium of a culture dish at a predetermined cell density, and removing the first culture medium after a first culture time to obtain a first cell intermediate; an activity stimulation step: preserving the first cell intermediate in a freezing container having a cell cryopreservation solution, and performing a constant temperature stimulation treatment or a variable temperature stimulation treatment for at least more than 1 day; and a product collection step: after completing the activity stimulation step, placing the freezing container in an environment at a thawing temperature for thawing, and then removing the cell cryopreservation solution to obtain the modified stem cell. The modified stem cell can release at least one or more of IL-4, IL-5, IL-13, G-CSF, Fractalkine, and EGF.
-
公开(公告)号：US20240115616A1
公开(公告)日：2024-04-11
申请号：US18376545
申请日：2023-10-04
Inventor： Po-Cheng Lin , Pi-Chun Huang , Zih-Han Hong , Ming-Hsi Chuang , Yi-Chun Lin , Chia-Hsin Lee , Chun-Hung Chen , Chao-Liang Chang , Kai-Ling Zhang
IPC: A61K35/28 , A61K9/00 , A61K9/127 , A61P1/16 , C12N5/0775
CPC classification number: A61K35/28 , A61K9/0019 , A61K9/127 , A61P1/16 , C12N5/0667 , C12N2500/02
Abstract: The present disclosure provides a method for treating liver cirrhosis by using a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors. The composition of the present disclosure achieves the effect of treating liver cirrhosis through various efficacy experiments.
-
公开(公告)号：US20170258841A1
公开(公告)日：2017-09-14
申请号：US15448050
申请日：2017-03-02
Inventor： Tsung-Ming LEE , Ming-Hsi CHUANG , Chun-Hung CHEN , Po-Cheng LIN , Chia-Hsin Lee
IPC: A61K35/28 , A61K9/00 , A61K31/5377 , A61K33/00 , A61K31/404
CPC classification number: A61K35/28 , A61K9/0019 , A61K31/404 , A61K31/5377 , A61K33/00 , A61K2300/00
Abstract: This invention provides a pharmaceutical compositions for treating arrhythmia. The pharmaceutical compositions comprise stem cells, pretreated with n-butylidenephthalide (BP).
-
公开(公告)号：US20230233613A1
公开(公告)日：2023-07-27
申请号：US17963219
申请日：2022-10-11
Inventor： Po-Cheng Lin , Pi-Chun Huang , Chia-Hsin Lee , Ming-Hsi Chuang , Chun-Hung Chen , Chao-Liang Chang , Kai-Ling Zhang , Yi-Chun Lin , Yu-Chen Tsai , Peggy Leh Jiunn Wong , Ruei-Yue Liang
IPC: A61K35/28 , A61K9/00 , C12N5/0789
CPC classification number: A61K35/28 , A61K9/0085 , A61K9/0019 , C12N5/0647 , C12N2501/10 , C12N2502/1382 , C12N2501/2304 , C12N2501/2313
Abstract: The present invention provides a pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising TS stem cells, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the TS stem cells is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1α, IL-1β, IL-4, IL-5, IL-13, IFNγ, TGFα and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.
-
5.发明公开公开(公告)号：US20230201266A1
公开(公告)日：2023-06-29
申请号：US17470487
申请日：2021-09-09
Inventor： Feng-Huei Lin , Che-Yung Kuan , Yu-Ying Lin , Ching-Yun Chen , Zhi-Yu Chen , I-Hsuan Yang , Ming-Hsi Chuang , Po-Cheng Lin , Chia-Hsin Lee , Kai-Ling Zhang , Pei-Syuan Chao , Wan-Sin Syu , Chun-Hung Chen , Ting-Ju Wang
IPC: A61K35/28 , A61P19/02 , C12N5/0775 , C12N5/00
CPC classification number: A61K35/28 , A61P19/02 , C12N5/0062 , C12N5/0667 , C12N2513/00 , C12N2533/30
Abstract: The present disclosure provides a method for treating arthritis by using a stem cell preparation. The stem cell preparation of the present disclosure can effectively delay cartilage degeneration caused by arthritis, and it is confirmed by whole blood analysis and blood biochemical analysis that the stem cell preparation in the form of three-dimensional stem cell spheres provides a safe treatment for arthritis. The present disclosure also provides a method for preparing the stem cell preparation.
-
Patent Agency Ranking
公开(公告)号：US20230193198A1
公开(公告)日：2023-06-22
申请号：US18066999
申请日：2022-12-15
Inventor： Ming-Hsi Chuang , Po-Cheng Lin , Chia-Hsin Lee , Mao-Hsuan Huang
IPC: C12N5/074
CPC classification number: C12N5/0607 , C12N2533/74 , C12N2500/98 , C12N2500/12 , C12N2500/32 , C12N2523/00
Abstract: A method for stably amplifying a pluripotent stem cell comprises the following steps: (a) a cell implantation step: implanting pluripotent stem cells directly into a porous scaffold such that the porous scaffold contains 1×104 or more of the pluripotent stem cells; and (b) a cell amplification step: immersing the porous scaffold in a specific culture medium which is xeno-free (XF) and performing amplification culture at an ambient temperature of 35.5-39.5° C. and a CO2 concentration of 5% to obtain the amplified pluripotent stem cells, wherein the amplified pluripotent stem cells aggregate to present an embryoid body state. The amplification method of the present disclosure can easily obtain an excellent effect of increasing an amplification multiple of the pluripotent stem cells to about 3 times or more.
-
公开(公告)号：US20250144150A1
公开(公告)日：2025-05-08
申请号：US19012977
申请日：2025-01-08
Inventor： Po-Cheng Lin , Pi-Chun Huang , Chia-Hsin Lee , Ming-Hsi Chuang , Chun-Hung Chen , Chao-Liang Chang , Kai-Ling Zhang , Yi-Chun Lin , Yu-Chen Tsai , Peggy Leh Jiunn Wong , Ruei-Yue Liang
IPC: A61K35/28 , A61K9/00 , A61K38/18 , A61K38/19 , A61K38/20 , A61K45/06 , A61P25/28 , C12N5/00 , C12N5/0775
Abstract: The present invention provides a preparation method of pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising adipose-derived stem cells treated by cell expansion, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the adipose-derived stem cells treated by cell expansion is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1α, IL-1β, IL-4, IL-5, IL-13, IFNγ, TGFα and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.
-
公开(公告)号：US20240075071A1
公开(公告)日：2024-03-07
申请号：US17993823
申请日：2022-11-23
Inventor： Ruei-Yue Liang , Kai-Ling Zhang , Ming-Hsi Chuang , Po-Cheng Lin , Peggy Leh Jiunn Wong , Chia-Hsin Lee
IPC: A61K35/28 , C12N5/0775
CPC classification number: A61K35/28 , C12N5/0667 , C12N2500/32 , C12N2500/38 , C12N2500/60 , C12N2500/90 , C12N2501/115 , C12N2501/15
Abstract: Disclosed in the present invention is an optimized cell transplant. The optimized cell transplant is formed by performing gene induction and modification on a mesenchymal stem cell in the form of a small molecule and protein composition. The expression levels of CD200 gene, Galectin-9 gene and VISTA gene can be increased synchronously after cell culture. Vector virus infection and plasmid transfection are not required in the cell preparation process, so that high biological safety and great clinical application value of cells are achieved. The optimized cell transplant is suitable for the technical field of mesenchymal stem cells applied to cell transplantation therapy, and the therapeutic effect of the optimized cell transplant is more excellent than that of the non-modified mesenchymal stem cell
-
公开(公告)号：US20230407262A1
公开(公告)日：2023-12-21
申请号：US18055409
申请日：2022-11-14
Inventor： Wei Wu Li , Tzyy-Wen Chiou , Horng-Jyh Harn , Shinn-Zong Lin , Ming-Hsi Chuang , Po-Cheng Lin , Chia-Hsin Lee , Mao-Hsuan Huang
IPC: C12N5/0775 , C12N5/079 , C07K14/435 , A61K38/17 , A61P25/00
CPC classification number: C12N5/0663 , C12N5/0618 , C07K14/435 , A61K38/17 , A61P25/00
Abstract: The present invention provides a medicine for treating a neurodegenerative disease, which employs LEFTY2 (Left-Right Determination Factor 2) generated by co-culturing mesenchymal stem cells of mammals with nerve cells having mutations in the APP (Amyloid precursor protein) gene, or a specific protein. The LEFTY2 has an effect of inhibiting Beta amyloid and a hyperphosphorylated neuronal microtubule-associated protein (Tau protein), without affecting the development of nerve cells and having the ability to promote the growth of the nerve cells; and the two types of proteins have a crucial impact on the neurodegenerative diseases.
-
公开(公告)号：US20240124844A1
公开(公告)日：2024-04-18
申请号：US18376459
申请日：2023-10-04
Inventor： Chia-Hsin Lee , Po-Cheng Lin , Yong-Cheng Kao , Ming-Hsi Chuang , Chun-Hung Chen , Chao-Liang Chang , Kai-Ling Zhang
IPC: C12N5/0775 , A61P19/02
CPC classification number: C12N5/0667 , A61P19/02 , C12N2500/32 , C12N2500/38 , C12N2501/10
Abstract: The present disclosure provides a method for preparing a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors, the composition prepared by the method, and use of the composition for treating arthritis. The composition of the present disclosure achieves the effect of treating arthritis through various efficacy experiments.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.014 seconds)
